These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29709229)

  • 1. Defibrillation testing is mandatory in patients with subcutaneous implantable cardioverter-defibrillator to confirm appropriate ventricular fibrillation detection.
    le Polain de Waroux JB; Ploux S; Mondoly P; Eschalier R; Strik M; Houard L; Pierre B; Buliard S; Klotz N; Ritter P; Haissaguerre M; Mahfouz K; Bordachar P
    Heart Rhythm; 2018 May; 15(5):642-650. PubMed ID: 29709229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation.
    Griksaitis MJ; Rosengarten JA; Gnanapragasam JP; Haw MP; Morgan JM
    Europace; 2013 Apr; 15(4):523-30. PubMed ID: 23333943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre experience with the second-generation subcutaneous implantable cardioverter defibrillator and the intermuscular two-incision implantation technique.
    Migliore F; Mattesi G; De Franceschi P; Allocca G; Crosato M; Calzolari V; Fantinel M; Ortis B; Facchin D; Daleffe E; Fabris T; Marras E; De Lazzari M; Zanon F; Marcantoni L; Siciliano M; Corrado D; Iliceto S; Bertaglia E; Zecchin M
    J Cardiovasc Electrophysiol; 2019 Jun; 30(6):854-864. PubMed ID: 30827041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
    Sasaki T; Nakamura K; Naito S
    Int Heart J; 2019 Mar; 60(2):466-469. PubMed ID: 30745542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sinus rhythm R-wave amplitude as a predictor of ventricular fibrillation undersensing in patients with implantable cardioverter-defibrillator.
    Ruetz LL; Koehler JL; Brown ML; Jackson TE; Belk P; Swerdlow CD
    Heart Rhythm; 2015 Dec; 12(12):2411-8. PubMed ID: 26272520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative Defibrillation Testing of Subcutaneous Implantable Cardioverter-Defibrillator Systems-A Simple Issue?
    Frommeyer G; Zumhagen S; Dechering DG; Larbig R; Bettin M; Löher A; Köbe J; Reinke F; Eckardt L
    J Am Heart Assoc; 2016 Mar; 5(3):e003181. PubMed ID: 27068637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance.
    Tjong FV; Brouwer TF; Smeding L; Kooiman KM; de Groot JR; Ligon D; Sanghera R; Schalij MJ; Wilde AA; Knops RE
    Europace; 2016 Nov; 18(11):1740-1747. PubMed ID: 26941338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-discharge defibrillation testing: Is it still justified?
    Kempa M; Królak T; Drelich Ł; Budrejko S; Daniłowicz-Szymanowicz L; Lewicka E; Kozłowski D; Raczak G
    Cardiol J; 2016; 23(5):532-538. PubMed ID: 27387062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to therapy delivery and effectiveness of the subcutaneous implantable cardioverter-defibrillator.
    Diemberger I; Migliore F; Ricciardi G; Ottaviano L; Tavoletta V; Francia P; Viani S; Capucci A; de Filippo P; Nigro G; Caravati F; Palmisano P; Ziacchi M; Lovecchio M; Valsecchi S; Bongiorni MG; Biffi M;
    Heart Rhythm; 2019 Oct; 16(10):1531-1537. PubMed ID: 31150817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.
    Kooiman KM; Knops RE; Olde Nordkamp L; Wilde AA; de Groot JR
    Heart Rhythm; 2014 Mar; 11(3):426-34. PubMed ID: 24321235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of shock therapy related to improper sensing of noise on the defibrillation test during subcutaneous implantable cardioverter-defibrillator implantation: a case report.
    Tamura S; Yoshiyama T; Doi A; Yoshiyama M
    Eur Heart J Case Rep; 2020 Dec; 4(6):1-6. PubMed ID: 33447710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Implantable cardioverter-defibrillator oversensing due to electric shock].
    Jurcević R; Angelkov L; Vukajlović D; Ristić V; Tomović M; Djukanović B
    Srp Arh Celok Lek; 2010; 138(3-4):236-9. PubMed ID: 20499508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of arrhythmia discrimination performance of subcutaneous and transvenous ICD arrhythmia detection algorithms: the START study.
    Gold MR; Theuns DA; Knight BP; Sturdivant JL; Sanghera R; Ellenbogen KA; Wood MA; Burke MC
    J Cardiovasc Electrophysiol; 2012 Apr; 23(4):359-66. PubMed ID: 22035049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of magnetic resonance imaging on ventricular tachyarrhythmia sensing: Results of the Evera MRI Study.
    Gold MR; Sommer T; Schwitter J; Kanal E; Bernabei MA; Love CJ; Surber R; Ramza B; Cerkvenik J; Merkely B
    Heart Rhythm; 2016 Aug; 13(8):1631-5. PubMed ID: 27196818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.